IL17A and non-small cell lung carcinoma: The enrichment of inflammation‐related signalling cascades—IL‐17 pathway, TNF signalling, complement activation—further emphasises the centrality of inflammatory processes in NSCLC pathogenesis and offers potential targets for therapeutic development.